Galectin Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Galectin Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 98% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 36% of its market value (net debt). Lower than 90% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-1,085.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 98% of Healthcare companies in United States.
Cash Cushion Ratio
−36%Debt, after subtracting cash, equals 36% of its market value (net debt).
Lower than 90% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Galectin Therapeutics Inc. made a loss over the last year. Galectin Therapeutics Inc. owes $10.2 for every $1 it owns. Galectin Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGalectin Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-2.35Galectin Therapeutics Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$322 MThe total market value of all of Galectin Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeGalectin Therapeutics Inc.'s net worth is negative ($137 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
10.2×Galectin Therapeutics Inc. owes $10.2 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Dividend yield
NoneGalectin Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossGalectin Therapeutics Inc. made a loss in each of the last two years.
Interest cover
Not coveredGalectin Therapeutics Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtGalectin Therapeutics Inc. had $116 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Galectin Therapeutics Inc. owe compared with what it owns?
Galectin Therapeutics Inc. owes $10.2 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Does Galectin Therapeutics Inc. pay a dividend?
No. Galectin Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.